Skip to main content

Aspect Biosystems

PlatformVancouver, British Columbia, CanadaFounded 2013· One of 206 Platform companies tracked by AMPulse

Aspect Biosystems develops bioprinted tissue therapeutics using AI-powered bioprinting technology, computational design tools, advanced biomaterials, and therapeutic cells.

CEO / Founder
Tamer Mohamed
Team Size
51-200
Stage
Active
Total Funding
$290M
Key Investors
Dimension; Novo Nordisk; Radical Ventures; Pallasite Ventures; Pangaea Ventures; Rhino Ventures; T1D Fund; InBC Investment Corp.; Endure Capital; Relentless Pursuit Partners

Technology & Products

Key Products

Aspect Biosystems develops bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions for metabolic and endocrine diseases. Their platform integrates bioprinting, computational design, therapeutic cells, and biomaterials.

Technological Advantage

Full-stack tissue therapeutic platform combining tissue engineering, cell therapy, biomaterials, computer vision, and robotics.

Differentiation

Value Proposition

Creating a new category of cellular medicines offering functional cures for metabolic and endocrine diseases.

How They Differentiate

Differentiates through an integrated AI-powered bioprinting platform that combines multiple advanced technologies, setting it apart from traditional tissue engineering approaches.

Market & Competition

Target Customers

Patients suffering from serious metabolic and endocrine ailments.

Industry Verticals

["Regenerative medicine","Tissue engineering","Cellular therapies"]

Competitors

Organovo; Cyfuse Biomedical; Other biotech firms in cellular therapies and biomaterials

Growth & Milestones

Growth Metrics

Advancing projects toward clinical trials and secured a C$200m collaboration with the Canadian and British Columbian governments.

Major Milestones

["Secured $115 million in Series B funding","Advancing multiple projects toward clinical trials","C$200m collaboration with Canadian and British Columbian governments"]

Notable Customers

Novo Nordisk

https://www.aspectbiosystems.com

Recent coverage of Aspect Biosystems

Why this company matters

Aspect Biosystems is developing a new class of cellular medicines by integrating bioprinting, computational design, advanced biomaterials, and therapeutic cells. The Vancouver-based company targets metabolic and endocrine diseases, aiming to produce functional cures rather than symptom management through implantable tissue therapeutics.

The company's full-stack platform combines material extrusion bioprinting with computer vision and robotics to fabricate living tissue constructs. These constructs are designed to replace, repair, or supplement biological functions, using selectively permeable cell-laden fiber structures and continuously bioprinted multilayer tissue architectures protected by a portfolio of 27 registered patents.

Aspect's lead partnership is with Novo Nordisk, a major pharmaceutical player in metabolic disease. The company has raised $290 million in total funding from investors including Dimension, Radical Ventures, and the T1D Fund, and secured a C$200 million collaboration with Canadian and British Columbian governments to advance projects toward clinical trials.

The primary competitive risk is the long and uncertain regulatory pathway for bioprinted tissue therapeutics, which must demonstrate safety and efficacy in humans. Competitors such as Organovo and Cyfuse Biomedical are pursuing similar goals, but Aspect's integration of AI-driven design and therapeutic cells may provide a differentiation advantage if clinical milestones are met.